» Articles » PMID: 35563166

Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 May 14
PMID 35563166
Authors
Affiliations
Soon will be listed here.
Abstract

The tetraspanin CD9 is considered a metastasis suppressor in many cancers, however its role is highly debated. Currently, little is known about CD9 prognostic value in cutaneous melanoma. Our aim was to analyse CD9 expression in melanocytic nevi and primary cutaneous melanomas through immunohistochemistry and immunofluorescence approaches to determine its correlation with invasiveness and metastatic potential. CD9 displayed homogeneous staining in all melanocytic nevi. In contrast, it showed a complete loss of reactivity in all thin melanomas. Interestingly, CD9 was re-expressed in 46% of intermediate and thick melanomas in small tumor clusters predominantly located at sites of invasion near or inside the blood or lymphatic vessels. The most notable finding is that all CD9 stained melanomas presented sentinel node positivity. Additionally, a direct association between CD9 expression and presence of distant metastasis was reported. Finally, we confirm that CD9 expression is consistent with an early protective role against tumorigenesis, however, our data endorse in melanoma a specific function of CD9 in vascular dissemination during late tumor progression. The presence of CD9 hotspots could be essential for melanoma cell invasion in lymphatic and endothelial vessels. CD9 could be a valid prognostic factor for lymph node metastasis risk.

Citing Articles

Bioinformatics investigation of the prognostic value and mechanistic role of CD9 in glioma.

Jiang J, Jiang B, Li W Sci Rep. 2024; 14(1):24502.

PMID: 39424846 PMC: 11489571. DOI: 10.1038/s41598-024-74109-w.


Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma.

Huser L, Chhabra Y, Gololobova O, Wang V, Liu G, Dixit A Cell Rep. 2024; 43(9):114721.

PMID: 39255061 PMC: 11835374. DOI: 10.1016/j.celrep.2024.114721.


Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review.

Rizzetto G, De Simoni E, Molinelli E, Offidani A, Simonetti O Int J Mol Sci. 2023; 24(15).

PMID: 37569757 PMC: 10419154. DOI: 10.3390/ijms241512383.


Prognostic value and multifaceted roles of tetraspanin CD9 in cancer.

Ondrussek R, Kvokackova B, Krystofova K, Brychtova S, Soucek K, Bouchal J Front Oncol. 2023; 13:1140738.

PMID: 37007105 PMC: 10063841. DOI: 10.3389/fonc.2023.1140738.


Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma.

Rizzetto G, Lucarini G, De Simoni E, Molinelli E, Mattioli-Belmonte M, Offidani A Int J Mol Sci. 2023; 24(1).

PMID: 36613587 PMC: 9820052. DOI: 10.3390/ijms24010144.

References
1.
Iwasaki T, Takeda Y, Maruyama K, Yokosaki Y, Tsujino K, Tetsumoto S . Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro. J Biol Chem. 2012; 288(4):2118-31. PMC: 3554885. DOI: 10.1074/jbc.M112.424291. View

2.
Choi D, Park J, Paek S, Choi S, Paek S . Detecting early-stage malignant melanoma using a calcium switch-enriched exosome subpopulation containing tumor markers as a sample. Biosens Bioelectron. 2021; 198:113828. DOI: 10.1016/j.bios.2021.113828. View

3.
Strashilov S, Yordanov A . Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. Int J Mol Sci. 2021; 22(12). PMC: 8232613. DOI: 10.3390/ijms22126395. View

4.
Huan J, Gao Y, Xu J, Sheng W, Zhu W, Zhang S . Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015; 8(3):3054-61. PMC: 4440126. View

5.
Rambow F, Malek O, Geffrotin C, Leplat J, Bouet S, Piton G . Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLiM swine model. Pigment Cell Melanoma Res. 2008; 21(2):147-61. DOI: 10.1111/j.1755-148X.2008.00442.x. View